BioVie to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary

BioVie Inc. (NASDAQ: BIVI) is participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13-14, 2024. The company's management team will be involved in the virtual event, showcasing its innovative drug therapies for advanced liver disease and neurological disorders.

CARSON CITY, Nev., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of advanced liver disease and neurological and neurodegenerative disorders, today announced the participation of its management team in the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024.

Oppenheimer 34th Annual Healthcare Life Sciences Conference
Thursday, February 14, 2024
Time: 12:40pm Eastern Time
Webcast Link: Click Here

Contact your Oppenheimer representative for additional information.

About BioVie

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (e.g., TNF signaling) that leads to neuroinflammation and insulin resistance, but not their homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both are drivers of Alzheimer’s and Parkinson’s diseases. The Company is conducting a Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease (NCT04669028). Results of a Phase 2 investigator-initiated trial (NCT05227820) showing NE3107-treated patients experienced improved cognition and biomarker levels were presented at the Clinical Trial in Alzheimer’s Disease (CTAD) annual conference in December 2022. An estimated six million Americans suffer from Alzheimer’s. A Phase 2 study of NE3107 in Parkinson’s disease (NCT05083260) has completed, and data presented at the International Conference on Alzheimer's and Parkinson's Disease and Related Neurological Disorders conference in Gothenburg, Sweden in March 2023 showed significant improvements in “morning on” symptoms and clinically meaningful improvement in motor control in patients treated with a combination of NE3107 and levodopa vs. patients treated with levodopa alone, and no drug-related adverse events. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the treatment of ascites due to chronic liver cirrhosis. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit http://www.bioviepharma.com/.

Forward-Looking Statements 

This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the risk that unblinded data is not consistent with blinded data, the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.

For Investor Relations Inquiries: 

Contact:  Bruce Mackle  Managing Director  LifeSci Advisors, LLC  bmackle@lifesciadvisors.com
For Media Inquires Melyssa Weible Managing Partner, Elixir Health Public Relations  Ph: +1 201-723-5705 mweible@elixirhealthpr.com

What is the date of the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

The conference will be held on February 13-14, 2024.

What is the webcast link for the conference?

The webcast link for the conference can be accessed by clicking here.

What is the ticker symbol for BioVie Inc.?

The ticker symbol for BioVie Inc. is BIVI.

What is the focus of BioVie Inc.'s drug therapies?

BioVie Inc. is developing innovative drug therapies for the treatment of advanced liver disease and neurological disorders.

Who is participating in the Oppenheimer 34th Annual Healthcare Life Sciences Conference?

BioVie Inc. is participating in the conference with its management team.

When is the presentation by BioVie Inc.'s management team scheduled?

The presentation by BioVie Inc.'s management team is scheduled for Thursday, February 14, 2024 at 12:40pm Eastern Time.